Confirmation of the predictive value of maspin parameter in the response to endocrine therapy in breast cancer patients needs a prospective randomised study to show that this parameter do influence the outcome only in patients who received adjuvant tamoxifen as compared with untreated patients. This evidence concerns the gene SERPINB5 and breast carcinoma.